Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Impact of elexacaftor/tezacaftor/ivacaftor on the presence of bacterial and fungal pathogens in the lower respiratory tract of children with cystic fibrosis
Avtorji:ID Setnikar Kimovec, Gaja (Avtor)
ID Seme, Katja (Avtor)
ID Matos, Tadeja (Avtor)
ID Špik, Vesna (Avtor)
ID Krivec, Uroš (Avtor)
ID Praprotnik, Marina (Avtor)
ID Rodman, Jasna (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,50 MB)
MD5: 08DAE352308AECABFF292C7A31AB820E
 
URL URL - Izvorni URL, za dostop obiščite https://www.resmedjournal.com/article/S0954-6111(26)00214-3/fulltext
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background: Highly effective CFTR modulator therapy, such as elexacaftor/tezacaftor/ivacaftor (ETI), has been linked to significant clinical improvements in people with cystic fibrosis (pwCF). However, its effect on the presence of respiratory pathogens in the lower respiratory tract of younger, mainly non-expectorant children with CF remains poorly understood, especially using lower airway sampling methods. We aimed to investigate changes in lower airway microbiology and clinical outcomes in children with CF aged 6-12 years before and after starting ETI. Methods: We conducted a prospective observational single-centre study including children with CF commencing ETI who had no prior exposure to CFTR modulators, inhaled antibiotics, or prophylactic antibiotics. Lower airway microbiology was assessed longitudinally using sputum or induced sputum (IS). Pathogen prevalence, sweat chloride concentration, pulmonary function, nutritional status, and rate of exacerbations were evaluated before and up to 12 months after ETI initiation. Results: Sixteen pwCF were included (median age 8.4 years, 69 % boys, 75% were F508del homozygous). None of the children was expectorant at any point during the study. Following ETI initiation, we observed decreased growth of methicillin-sensitive Staphylococcus aureus and Aspergillus fumigatus, reduced variability in fungal populations, and an increase in negative bacterial and fungal culture results. Conclusions: In this exploratory study of young, modulator-naïve children with CF, ETI initiation was associated with changes in the lower airway microbiology composition assessed by IS. These findings highlight potential shifts in lower airway microbiology and the importance of age-appropriate lower airway sampling in future paediatric studies.
Ključne besede:children, cystic fibrosis, elexacaftor/tezacafot/ivacaftor, respiratory pathogens
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2026
Št. strani:str. 1-7
Številčenje:Vol. 257, iss. [Article no.] 108846
PID:20.500.12556/DiRROS-29220 Novo okno
UDK:616.2-053.2:577
ISSN pri članku:1532-3064
DOI:10.1016/j.rmed.2026.108846 Novo okno
COBISS.SI-ID:276097795 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 22. 4. 2026;
Datum objave v DiRROS:24.04.2026
Število ogledov:28
Število prenosov:15
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Respiratory medicine
Skrajšan naslov:Respir. med.
Založnik:Elsevier
ISSN:1532-3064
COBISS.SI-ID:518761241 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0458-2025
Naslov:Prirojene in pridobljene okvare imunosti

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:otroci, cistična fibroza, eleksakaftor/tezakafot/ivakaftor, respiratorni patogeni


Nazaj